Immune Design Corp.
RETROVIRAL VECTOR FOR THE ADMINISTRATION AND EXPRESSION OF REPLICON RNA EXPRESSING HETEROLOGOUS NUCLEIC ACIDS

Last updated:

Abstract:

The present disclosure relates generally to gene delivery using a chimeric, retroviral-RNA replicon vector particle for increased expression of transgenes in a host cell. In particular, the chimeric vectors described herein can be used in any of a variety of settings including gene therapy and vaccine settings.

Status:
Application
Type:

Utility

Filling date:

3 Sep 2021

Issue date:

24 Feb 2022